SCHEMBL1428360

SCHEMBL1428360

CN(CCCCNC(=O)OC(C)(C)C)CCNC(=O)c1nc(Cl)c(N)nc1N

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
STK17B O94768 1/20 0.39
STK17A Q9UEE5 1/20 0.39
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
SCNN1A P37088 3/20 0.36
NPSR1 Q6W5P4 2/20 0.36
CSNK2A2 P19784 1/20 0.36
CSNK2A1 P68400 1/20 0.36
CKS1B P61024 1/20 0.36
SKP1 P63208 1/20 0.36
SKP2 Q13309 1/20 0.36
CA12 O43570 2/20 0.35
CA1 P00915 2/20 0.35
CA2 P00918 2/20 0.35
CA9 Q16790 2/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1134533 0.89 TDP1 (0.49) KCNH2TDP1STK17BSTK17AMAOA
SCHEMBL2287885 0.82 SCNN1A (0.41) KCNH2TDP1MAOASCNN1ANPSR1
SCHEMBL1428384 0.81 SCNN1A (0.39) KCNH2TDP1MAOASCNN1ANPSR1
SCHEMBL1134522 0.80 TDP1 (0.40) KCNH2TDP1STK17BSTK17AMAOA
SCHEMBL16541825 0.80 TMEM97 (0.46) KCNH2MEN1KMT2A
SCHEMBL16541840 0.80 TMEM97 (0.53) NPSR1KMT2APOLB
SCHEMBL16541819 0.80 TMEM97 (0.51) KCNH2TDP1SCNN1AGAA
SCHEMBL4884842 0.79 SCNN1A (0.44) TDP1STK17BSTK17AMAOAMAOB
SCHEMBL4885148 0.79 SCNN1A (0.44) TDP1STK17BSTK17AMAOAMAOB
SCHEMBL4883729 0.79 SCNN1A (0.44) TDP1STK17BSTK17AMAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2300010-B1 PYRAZINE DERIVATIVES AS EPITHELIAL SODIUM CHANNEL BLOCKERS NOVARTIS AG (CH) 2015-03-04 EP disclosed
US-8236808-B2 Pyrazine derivatives as ENAC blockers NOVARTIS AG (CH) 2012-08-07 US disclosed
US-20110201625-A1 Organic Comopunds NOVARTIS AG (CH) 2011-08-18 US disclosed
EP-2300010-A2 ORGANIC COMPOUNDS Novartis AG (CH) 2011-03-30 EP disclosed
WO-2009150137-A2 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201625-A1 Organic Comopunds OR10J3, CFTR, CLIC1 KCNH2 49/4885TDP1 3901/4885STK17B 2894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.